GE reveals new company names as it approaches historic split

GE reveals new company names as it approaches historic split


People visit the General Electric stand during the China International Import Expo (CIIE) at the National Exhibition and Convention Center on November 7, 2018 in Shanghai, China.

VCG | Getty Images

General Electric on Monday revealed the names of the three distinct companies that will result from the conglomerate’s historic split: GE HealthCare, GE Aerospace and GE Vernova.

GE HealthCare will encompass the company’s health services branch and will be listed on the Nasdaq under the symbol “GEHC,” the company said in a release. That spin-off is expected to be completed early next year.

GE Aerospace will encompass the company’s aviation branch, which includes a fleet of 39,400 commercial and 26,200 military aircraft. The aerospace offshoot will also own the GE trademark, which it can license out to the other divisions.

The company’s renewable energy businesses will fall under the name GE Vernova — a title the company said is “a combination of ‘ver,’ derived from ‘verde’ and ‘verdant’ to signal the greens and blues of the Earth, and ‘nova,’ from the Latin ‘novus,’ or ‘new,’ reflecting a new and innovative era of lower carbon energy that GE Vernova will help deliver.”

GE maintains an installed base of 7,000 gas turbines and 400 gigawatts of renewable energy equipment. The spin-off of that business is expected to be completed in early 2024.

“Today marks a key milestone in GE’s plan to become three independent, laser-focused companies,” Chairman and CEO Larry Culp said in a statement. “Leveraging GE’s multi-billion-dollar global brand gives us a competitive advantage in our end markets, allowing these businesses to win in the future.”

Shares of GE were up about 2% in morning trading Monday amid broader market gains. The stock is down roughly 30% so far in 2022.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More